Crowdsourced drug discovery can widen the search for treatments that commercial research has overlooked, but a screening hit is only a starting point. Distributed projects contribute compounds, synthesis, assays, computing, data, or expertise; specialists must still validate activity, optimize the chemistry, establish safety, and run clinical trials. DNDi’s Open Synthesis Network, Mycetoma Open Source project, compound-screening campaigns, and industry collaborations show how these models work without implying that every old compound is already a cure.
What crowdsourced drug discovery means in practice
In neglected-disease research, “crowdsourced” is best understood as distributed contribution rather than a single public contest. Different participants may provide an existing compound collection, make new analogues, run an assay, analyze data, or contribute funding and disease expertise. The project owner defines the pathogen, target, assay, data rules, and decision gates.
As an Amazon Associate I earn from qualifying purchases.
DNDi describes its role as coordinating projects with the international research community, public-sector institutions, pharmaceutical companies, and other partners. Its Open Synthesis Network uses chemistry teaching laboratories to design compounds that DNDi can test for anti-parasitic activity. The network includes more than 20 participating institutions, according to DNDi’s current Drug Discovery page (accessed 2026; the page text gives no publication year for that cumulative figure).
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteThat arrangement is collaborative but not necessarily unrestricted. A teaching lab may make a molecule to a shared specification while a specialist laboratory performs the biological test. In another project, structures and protocols may be public while some screening data, licensing terms, or follow-up work remain governed by agreements. Readers should ask what is open, who contributes, and what happens to the resulting intellectual property instead of treating “open” as a universal label.
#1 Best Overall
- FOR BASIC TEACHING TO ADVANCED SCIENCE: 444 pieces molecular model kit, including 136 atoms, 158 bonds and 150 parts for Carbon-60(Fullerene), provides to students from Grade 7 to Graduate level.
- TWO CHEMICAL STRUCTURE MODELS: The ball-and-stick models use spheres to represent atoms and sticks to represent chemical bonds. In the space-filling model, the spheres are drawn to scale and are next to one another as atoms are in real molecules.
- CHEMISTRY EDUCATIONAL MOLECULE MODEL IN 3D: It can display chemical structure, molecular bond, and bond angle in all directions. Demonstrate fundamental molecular geometry, chemical molecular structure, stereochemistry with 3D modeling studies.
- EASY TO LEARN: The universal standard adopted for each atom's color makes it easier for you to use and learn. Atoms and chemical bonds combine tightly and firmly and can be easily disassembled by disconnecting tools.
- If you’re not in love with it for whatever reason, we’ll give you a full replacement or refund—no questions asked. If you have any doubt, please tell us. With nothing to worry about, or even to share with your friends, try it now.
Why neglected diseases need distributed research
Neglected diseases often impose a large health burden in populations with limited purchasing power, creating a mismatch between medical need and expected commercial return. DNDi’s 2013 analysis reported that, from 2000 to 2011, 4% of new drugs and vaccines approved for all diseases were for neglected diseases, compared with an 11% health burden; it also reported that 1% of new drugs were for neglected diseases. Those are historical figures from that 2013 report, not current global estimates.
Distributed work can bring additional laboratories into a field, make use of idle equipment and chemical expertise, and reduce duplicated experiments. DNDi states: “Science works through sharing and collaborating, and doing so can notably attract additional world-class researchers to a neglected field, enabling better results, faster and cheaper by reducing duplication.” The benefit is organizational as much as chemical: a promising result can move to the group best equipped for the next experiment.
Costs still occur at every stage. DNDi’s 2013 report listed report-specific historical estimates including EUR 12 million for development and implementation monitoring of ASAQ, EUR 6.8 million for NECT, EUR 11.5 million for SSG&PM, and estimates of EUR 38.3 million for SCYX-7158 and EUR 26.5 million for fexinidazole. These figures describe particular programs and periods; they are not directly comparable current budgets or a general price list for drug development.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Rank #2
- Visualize Molecular: The molecular model kit simplifies complex chemistry concepts into tangible 3D structures improve learning efficiency, suitable for students from Grade 7 to Graduate level.
- 444 Pcs Complete Set: The atom model kit includes with 136 atoms,158 bonds, and 150 fullerene model parts, explore most the molecules structures from simple compounds to complex polymers.
- Effortless Assembly: Embedded component design ensures easy to construct Ball-and-stick and Space-filling models that maximizes focus on exploration without complex assembly.
- Durable & Portable: Built to last, the chemistry set is crafted from high-quality materials. Plus, its portable Snap-Lock design allows you to take your experiments learning anywhere, between the home, classroom and lab.
- Essential Study Tool: Whether you're studying organic chemistry, biochemistry, or molecular biology, molecule building kit is an perfect learning tool for you deeper comprehension of molecular science.
From a compound collection to a candidate
Drug discovery is a sequence of filters, not a single experiment.
- Choose the disease and assay. Researchers specify the organism or molecular target, the biological readout, concentration range, controls, and criteria for a reproducible signal.
- Run primary screening. A large collection is tested to find “hits”—compounds that meet the assay’s activity threshold. A hit may be toxic to the test cells, interfere with the assay, or fail in a different experimental format.
- Confirm and evaluate hits. Teams repeat the test, check concentration-response behavior, measure selectivity against host cells, and verify the compound’s identity and purity.
- Optimize a lead series. Chemists make related analogues to improve potency, stability, exposure, solubility, and safety while preserving activity against the pathogen.
- Nominate a preclinical candidate. A candidate needs a coherent package of pharmacology, toxicology, manufacturing, and formulation evidence before human studies.
- Conduct clinical development. Phase 1 through phase 3 studies test safety, dosing, efficacy, and benefit-risk in people. Regulatory approval and access programs are separate decisions.
DNDi says its discovery process includes screening, evaluating leads, and optimization, and combines repurposing or modifying known compounds with discovering new chemical entities. Therefore, a screen result is evidence for the next experiment—not proof of clinical efficacy or approval.
What DNDi’s screening numbers tell you
DNDi reports that it has screened more than 3 million compounds for Leishmania and Trypanosoma cruzi, and 1.5 million for Trypanosoma brucei. These are cumulative figures on the current Drug Discovery page, accessed in 2026, without a publication year in the page text. They indicate the scale of the search, not the number of medicines produced. Large libraries inevitably yield many inactive compounds and require substantial confirmation and optimization work.
Rank #3
- UNLOCK YOUR CHEMISTRY POTENTIAL: Our comprehensive molecular model kit includes 238 pieces, featuring 84 atoms, 153 bonds and a remover tool. Suitable for chemistry learners from beginners to advanced levels. Manufacturer recommended age: 15 years and up
- ORGANIZED STORAGE AND EASY LOCATING: Experience hassle-free organization with our storage box, complete with divided compartments and labeled sections. Say goodbye to clutter and quickly find the components you need
- EXTRA LEARNING MATERIALS FOR EXCELLENCE: Enhance your studies with our bonus 6-page learning guide and stencils. From grade 9 to college, from organic to inorganic, finish and master your assignments faster and create numerous molecular structures with ease
- IMMERSIVE 3D VISUAL LEARNING: Explore chemistry in a captivating way with our 3D visual learning approach. The universal color-coded Atomic Balls provide a better understanding of molecular structure, boosting your chemistry knowledge. It's also a perfect gift for someone who are going to learn those complex molecule
- EASY-TO-USE DESIGN: Crafted from smooth, burr-free plastic, our molecular science kit ensures easy assembly. With the included remover tool, disassembling is a breeze
Collections can also be reused across disease questions. The Medicines for Malaria Venture Pathogen Box, described in DNDi’s 2025 open-science policy report, gives researchers free access to 400 compounds active against bacteria, viruses, or fungi. The report describes an expectation that generated data be shared in the public domain within two years. Free access to a compound and a data-sharing expectation can accelerate testing, but neither establishes that a particular compound treats a neglected disease.
The Malaria Box has similarly been explored beyond its original purpose. A 2016 PLOS Pathogens article describes open-source screening with that collection for neglected diseases and other indications (PLOS Pathogens, 2016). Such work shows how a curated chemical starting point can be redeployed; it does not turn every active well into a safe therapy.
Three collaboration models and their boundaries
| Model | Who contributes | What may be open | Typical stage | Important boundary |
|---|---|---|---|---|
| Open Synthesis Network | Chemistry teaching labs and DNDi-linked researchers; more than 20 institutions are cited by DNDi | Design and synthesis instructions may be coordinated across participants; testing is organized by project partners | New compound synthesis and early screening | Participation does not mean every contributor independently tests compounds or that all project information is unrestricted |
| Mycetoma Open Source | A transparent, community-driven effort involving researchers working on fungal mycetoma | Project information and collaboration are intended to be transparent, subject to the project’s operating arrangements | Discovery and development work for a defined disease | Transparency does not by itself demonstrate a clinical candidate or approved treatment |
| Pathogen Box exploration | Researchers using a free set of 400 compounds supplied through MMV | Compound access and a public-data expectation described by DNDi’s 2025 report | Screening and follow-up evaluation | Activity in an assay still requires confirmation, optimization, safety work, and clinical evidence |
| NTD Drug Discovery Booster | Participating pharmaceutical companies screening millions of compounds simultaneously | Hit-compound commitments depend on whether seed compounds were public-domain/DNDi or company-owned | Large-scale screening and hit sharing | Its industry agreements and intellectual-property rules differ from open-synthesis projects |
DNDi says the NTD Drug Discovery Booster launched in 2015 so participating companies could screen millions of compounds at the same time. The resulting commitments depend on the origin of the seed compound: public-domain or DNDi material is treated differently from company-owned material. This is a useful reminder that “crowdsourced” covers several governance models, not one standard license.
Rank #4
- ADVANCED LEARNING SCIENCE EDUCATION KIT --- Perfect chemistry model kit for modeling simple and small to more advanced and complex chemical structures for schools and college level, students of all ages, researchers and enthusiasts. Fun and interactive early learning molecular set for kids of all years and for use in the classroom.
- HIGH QUALITY --- Made from high quality durable materials designed for easy construction and perfect fit. These Molecular Model Kit pieces are color coded to national standards for easy ID. Organic Chemistry Model Kit includes box for easy storage and transport with your other textbooks, notes, and books. Excellent for the classroom.
- POWERFUL FUNCTIONS --- This Molecular Model Kit has a total of 136 pieces including short link remover tool. Super easy to build models for organic and inorganic chemistry, This model contains C, H, O, N, S and a variety of single and double bonds, Can be put high school, university chemistry in most of the organic or inorganic molecular structure model for the study of experimental operation.
- QUICK AND EASY ASSEMBLY OF COMPLEX STRUCTURES --- Atoms and bonds that are perfectly suited to being connected and disconnected easily without making your fingers hurt. We've also included a link remover to make the task of easy.
- CONVENIENT STORAGE --- The pieces come in a slim plastic box for convenient storage. See the pictures on this listing for a full understanding of what's inside
Open science in a real disease program: mycetoma
Mycetoma is a chronic infection that can be caused by fungi or bacteria and can lead to severe disability. DNDi’s Mycetoma Open Source project is described as a transparent, community-driven effort focused on fungal mycetoma. Its value is not a claim that a particular half-forgotten compound already works. Instead, the model lets researchers coordinate disease biology, chemistry, testing, and data around a condition that has historically attracted limited investment.
For a project like this, useful openness can include publishing the disease problem and assay methods, reporting negative as well as positive results, and making validated chemical and biological data reusable. The practical test is whether another qualified laboratory can understand what was done, reproduce the result, and see what work remains.
Free tools Windows power users keep installed
One-click scans. No signup required.
How an old compound can—and cannot—be repurposed
A previously known molecule can provide a shortcut to chemistry, manufacturing knowledge, or an existing safety record. DNDi’s 2025 annual report says acoziborole was initially identified in Anacor Pharmaceuticals’ chemical library and then optimized with Scynexis and Pace University. That history illustrates reuse of a chemical starting point followed by substantial project-specific work.
Best Value
- Visualize Molecular: The molecular model kit simplifies complex chemistry concepts into tangible 3D structures improve learning efficiency, suitable for students from Grade 7 to Graduate level.
- 240 Pcs Complete Set: The atom model kit includes with 86 atoms and 154 bonds, explore most the molecules structures from simple compounds to complex polymers.
- Effortless Assembly: Embedded component design ensures easy to construct Ball-and-stick and Space-filling models that maximizes focus on exploration without complex assembly.
- Durable & Portable: Built to last, the chemistry set is crafted from high-quality materials. Plus, its portable design allows you to take your experiments learning anywhere, between the home, classroom and lab.
- Essential Study Tool: Whether you're studying organic chemistry, biochemistry, or molecular biology, molecule building kit is an perfect learning tool for you deeper comprehension of molecular science.
Repurposing is not a presumption of efficacy. A compound used for one disease may fail against a different pathogen, reach the wrong tissue, have an unsuitable dose, or show unacceptable toxicity when administered for a new indication. Researchers must generate evidence for the specific compound-disease pair: replicated activity, selectivity, pharmacokinetics, toxicology, and, eventually, clinical outcomes.
How to judge a “crowdsourced cure” claim
- Identify the stage. Is the claim about a computational prediction, a single screening hit, a confirmed lead, a preclinical candidate, a clinical study, or an approved treatment?
- Check the assay. Activity against a purified target, cultured cells, or an animal model answers different questions. None alone proves human benefit.
- Look for controls and replication. A credible result reports controls, concentration-response data, repeat experiments, and counter-screens for toxicity or assay interference.
- Separate compound identity from treatment identity. A library code or chemical name is not the same as a formulated medicine with a tested dose.
- Read the access terms. “Open” may cover structures and protocols while licensing, manufacturing, or unpublished follow-up remains restricted.
- Demand disease-specific evidence. Do not infer that a compound treats a neglected disease merely because it was known, inexpensive, or active in another context.
What success would look like
A successful distributed project leaves a traceable chain from contribution to decision: the source of the compound or synthesis, the assay and controls, reproducible hit data, reasons for advancing or rejecting analogues, and an explicit plan for preclinical and clinical work. It should also make negative results useful, because knowing that a chemical series failed for toxicity or exposure prevents another laboratory from repeating the same dead end.
DNDi’s broader purpose is to close R&D gaps, not to present screening volume as a finished medicine. Its 2025 annual report quotes Executive Director Dr Luis Pizarro: “Developing the medicines that neglected communities have gone without for generations is a lifeline, not a luxury that can wait for easier times or be traded away for short-term savings.” Crowdsourced chemistry can make that effort broader and less duplicative, but patients benefit only when the later validation, trials, approval, and delivery steps are completed.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsBottom line
Distributed drug discovery is a way to combine more compounds, laboratories, and expertise against diseases that conventional markets often underserve. DNDi’s open synthesis, mycetoma, Pathogen Box, and Booster examples show distinct approaches to contribution, openness, and intellectual property. The responsible conclusion is narrower than “forgotten drugs cure neglected diseases”: shared screening can reveal starting points, while rigorous optimization and clinical evidence determine whether any starting point becomes a treatment.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
